---
schema_version: "secwatch.filing_event.v1"
accession: "0001645113-25-000032"
form_type: "8-K"
ticker: "NVCR"
cik: "0001645113"
company_name: "NovoCure Ltd"
filed_at: "2025-08-28T23:59:59+00:00"
generated_at: "2026-05-17T09:28:57.148308+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# NovoCure terminates LUNAR-4 phase 2 trial for metastatic NSCLC, cites real-world evidence alternative

## Summary
- Novocure GmbH terminated the LUNAR-4 phase 2 trial of Tumor Treating Fields with pembrolizumab for metastatic non-small cell lung cancer.
- Decision based on availability of real-world evidence to achieve trial objectives without an interventional clinical study.
- Termination is not related to any safety concerns; no impact on other Novocure studies.
- Trial targeted patients previously treated with PD-1/PD-L1 inhibitor and platinum-based chemotherapy.

## SEC filing metadata
- accession: 0001645113-25-000032
- form_type: 8-K
- ticker: NVCR
- cik: 0001645113
- company_name: NovoCure Ltd
- filed_at: 2025-08-28T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645113/000164511325000032/0001645113-25-000032-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645113/000164511325000032/nvcr-20250828.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001645113-25-000032
- JSON: https://secwatch.observer/filing/0001645113-25-000032.json
- Plain text: https://secwatch.observer/filing/0001645113-25-000032.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.